Skip to Main Content

Paper Details

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
PLoS One
56
2020
(MMR) genes, MMR deficiency, MMRd, MSI, MSI-, Mismatch repair deficiency, PC, PD-1, PSA, PSA50, mCRPC, men, metastatic PC, metastatic castration resistant prostate cancer, metastatic prostate cancer, microsatellite instability, patients, pembrolizumab
Author NameAffiliation
Bruce MontgomeryUniversity of Washington
Bruce Montgomery
Heather H ChengUniversity of Washington
Heather H ChengClinical Research Division, Fred Hutchinson Cancer Research Center
Evan Y YuUniversity of Washington
Evan Y YuClinical Research Division, Fred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonClinical Research Division, Fred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington
Peter S NelsonClinical Research Division, Fred Hutchinson Cancer Research Center
Peter S NelsonFred Hutchinson Cancer Research Center
Colin C PritchardUniversity of Washington
  • 1 - 13

Datasets

Release 1.2